Global Brand Lead, Navtemadlin
Ipsen
Summary
The Global Brand Lead, Navtemadlin (GBL, Nav) is a senior commercial leader responsible for shaping and delivering the brand strategy for Navtemadlin, a Phase 3 oncology therapeutic in late-stage development. Based in the US, this role leads integrated brand planning, translates asset strategy into clear commercial priorities, and mobilizes cross-functional global, regional, and US teams to support late-stage development, launch readiness, and long-term brand value.
Job description
Main Responsibilities
Brand Strategy & Portfolio Leadership
- Develop and execute the integrated brand strategy for Navtemadlin to maximize long-term asset value and patient impact.
- Translate portfolio and asset objectives into clear commercial priorities, strategic initiatives, and measurable business outcomes.
Launch & Growth Execution
- Lead late-stage development commercialization planning and launch readiness activities for a Phase 3 oncology therapeutic, with a strong focus on US market requirements.
- Drive lifecycle management strategies that accelerate growth, expand market opportunities, and sustain brand performance.
Cross-Functional Leadership
- Lead and influence a global matrix team across Commercial, Medical, Market Access, Regulatory, Finance, Supply Chain, and other key functions.
- Build alignment across global and local stakeholders to ensure effective decision-making and execution.
Customer & Market Insight
- Leverage customer, patient, competitor, and market insights to identify opportunities, mitigate risks, and inform strategic choices.
- Ensure strategies are grounded in evolving market dynamics and stakeholder needs.
Performance & Governance
- Define performance metrics, monitor results, and drive course corrections to achieve business objectives.
- Ensure all activities are executed in compliance with company policies and applicable regulations.
Requirements
- BA/BS (undergraduate degree) in business or life sciences is required
- MBA or advanced degree is preferred
- 15+ years of experience in the pharmaceutical or biotechnology industry, including global or regional marketing, brand strategy, asset strategy and launch leadership roles
- Demonstrated late-stage development, pre-launch, and global launch experience, including in the U.S
- Experience in oncology and especially in hematology is preferred
- Proven track record of developing and executing global brand strategies in collaboration with Medical, Market Access, Regulatory, Development, and Commercial functions
- Strong understanding of launch readiness, lifecycle management, evidence generation, market access across major markets, and global-to-local execution
- Demonstrated ability to lead and influence cross-functional, cross-cultural matrix teams with and without direct authority
- Fluent English is required
- Additional languages e.g., French or other a benefit
Benefits
- 401(k) Matching
- Medical, Dental & Vision
- Life Insurance
- Disability Insurance
- Flexible Spending Accounts
- Parental Leave
- Paid Time Off
- Winter Shutdown
- Well-being Allowance
- Commuter Benefits
Company overview
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a global presence in over 40 countries. Founded in 1929 by Henri Beaufour, the company has evolved into a leading mid-size pharmaceutical firm specializing in three key therapeutic areas: oncology, rare diseases, and neuroscience. With approximately 5,300 employees worldwide, Ipsen operates as a publicly traded company on Euronext Paris while maintaining significant family ownership through the Beaufour family. The company's portfolio includes innovative treatments such as Cabometyx for advanced cancers, Dysport for neurological conditions, and Bylvay for rare liver diseases. Ipsen has established itself as one of the world's top 15 biopharmaceutical companies in oncology sales, with medicines registered in 88 countries and direct commercial operations in over 30 nations. The company maintains four global R&D hubs and three pharmaceutical development centers, investing significantly in research and development to advance transformative medicines for patients with limited treatment options.